in heavily pre treated mCRPC
Although the last participants in cohort 3 only completed dosing in January 2024, 60% of participants across all cohorts so far showed reductions in prostate-specific antigen (PSA) levels of greater than 35% from a single dose of Cu-67 SAR-bisPSMA. Twenty-seven percent of participants showed reductions in PSA levels of greater than 80%," the company said.